HK/China Healthcare Analyst (ex-Fosun Pharma)

Xinyao (Criss) Wang

Over 15 years' experience in both finance and healthcare, covering clinic operations, investment and equity research in both China and overseas.

Akeso Biopharma Placement (9926.HK) - The Concerns Behind and the Outlook

MicroPort MedBot (2252.HK)- Lack an “anchor” for Valuation Due to Uncertainties in Commercialization

Topsports International (6110.HK) - Has the Potential to Turn Things Around Despite the Headwinds

Ping An Good Doctor (1833.HK) - A Vicious Cycle?

Ping An Healthcare and Technology (1833.HK) - Untenable Business Model Worsen the Logic and Outlook

JD Health (6618.HK) - Logic Change Due to the New Policy?

Gravity Works As WeWork Doesn't; Now Plan B

Equity Bottom-Up

Alibaba Health Information Tec / Equity Bottom-Up

<ul>
<li>Alibaba Health’s core pharmaceutical direct sales business is facing challenges in terms of increasing competition as well as lower revenue growth and margins, dragging down the overall performance.</li>
<li>The recent new policies about online drug sales on third-party digital healthcare platforms and online diagnosis and treatment would add more uncertainties on Alibaba Health’s business and outlook.</li>
<li>If such unfavorable trend continues, the gap between Alibaba Health and JD Health would be wider. It’s not easy to break the deadlock. Investors may need to take heed.</li>
</ul>


Alibaba Health’s core pharmaceutical direct sales business is facing challenges in terms of increasing competition as well as lower revenue growth and margins, dragging down the overall performance.
The recent new policies about online drug sales on third-party digital healthcare platforms and online diagnosis and treatment would add more uncertainties on Alibaba Health’s business and outlook.
If such unfavorable trend continues, the gap between Alibaba Health and JD Health would be wider. It’s not easy to break the deadlock. Investors may need to take heed.


Yixintang Pharmaceutical Group (002727 CH)

DaShenLin Pharmaceutical Group (603233 CH)

Alibaba Health Information Technology (241.HK) - It’s Not Easy to Break a Deadlock